Curasight A S Is A Danish Biotechnology Company Founded In 2013Based In Copenhagenthe Company Specializes In Cancer Diagnostics And Therapeuticsfocusing On Precision Oncology Through Its Proprietary Upar Theranostics Platformthis Platform Combines Diagnostic Imaging And Targeted Radiation Therapy To Enhance Cancer Detection And Treatment Curasight S Core Technologies Include Utracea Diagnostic Imaging Tool That Uses Positron Emission Tomographypetto Target The Urokinase Type Plasminogen Activator Receptorupar Which Is Often Overexpressed In Aggressive Cancersthe Company Also Offers Utreata Targeted Radionuclide Therapy That Delivers Radiation Directly To Upar Positive Cancer Cellsminimizing Damage To Healthy Tissuecurasight S Pipeline Addresses High Mortality Cancers Such As Prostate Cancerglioblastomaand Pancreatic Canceramong Othersthe Company Holds Several Patents Related To Experimental Cancer Drugs And Medical Imagingreinforcing Its Commitment To Advancing Cancer Carecurasight Is Publicly Listed On The Nordic Growth Market And Is Dedicated To Improving Outcomes For Cancer Patients Through Its Innovative Solutions
